2. Search Result
Search Result
Results for "

ASPC-1

" in MedChemExpress (MCE) Product Catalog:

66

Inhibitors & Agonists

2

Fluorescent Dye

1

Peptides

1

Inhibitory Antibodies

1

Natural
Products

2

Isotope-Labeled Compounds

4

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0113
    Omeprazole
    5+ Cited Publications

    H 16868

    		 Na+/K+ ATPase Proton Pump Bacterial Cytochrome P450 Apoptosis Autophagy Atg8/LC3 TNF Receptor Interleukin Related Infection Neurological Disease Inflammation/Immunology Cancer
    Omeprazole (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects [1] .
    Omeprazole
  • HY-13594
    Chlorin e6
    Maximum Cited Publications
    18 Publications Verification

    Ce6

    		 MOFs Bcl-2 Family Caspase PARP Apoptosis Fluorescent Dye Infection Cancer
    Chlorin e6 is a photosensitizer and has strong absorption peaks at wavelength of 402 and 662 nm, as well as exhibiting intense fluorescence at 668 nm. Chlorin e6 has antimicrobial efficacy and anticancer activity. Chlorin e6 induces cell apoptosis via caspase-3 activation and can be used for the research of cancer [1] .
    Chlorin e6
  • HY-10805
    Almorexant
    5+ Cited Publications

    ACT 078573

    		 Orexin Receptor (OX Receptor) Calcium Channel Caspase Apoptosis Neurological Disease Endocrinology Cancer
    Almorexant (ACT 078573) is an orally active, potent and competitive dual orexin receptor antagonist, with Kd values of 1.3 nM (OX1) and 0.17 nM (OX2), respectively. Almorexant reversibly blocks signaling of orexin-A and orexin-B peptides. Almorexant totally blocked the intracellular Ca 2+ signal pathway. Almorexant stimulates caspase-3 activity in AsPC-1 cells and induces apoptosis [1] .
    Almorexant
  • HY-148273
    Setidegrasib

    ASP-3082; KRAS G12D inhibitor 17

    		 PROTACs Ras ERK Akt Cancer
    Setidegrasib (KRAS G12D inhibitor 17, ASP3082) is a PROTAC KRAS degrader (DC50: 37 nM). Setidegrasib induces the degradation of G12D-mutation KRAS protein. Setidegrasib suppresses p-ERK, p-AKT, p-S6 levels in AsPC-1 cells. Setidegrasib exhibits anti-tumor activity in various cancer xenograft models in mice. Setidegrasib can be used for the study of KRAS(G12D)-mutated solid tumors. (Blue: VHL ligase ligand (HY-168699); Black: linker (HY-168698); Pink: G12D ligand (HY-168700)) [1] .
    Setidegrasib
  • HY-158409
    Pan-RAS-IN-2

    		Molecular Glues Ras Cyclophilin PERK Cancer
    Pan-rasin-2 (compound 6A) is an orally active molecular glues that targets RAS. Pan-RAS-IN-2 inhibits pERK (IC50 in AsPC-1 cells: 0.3 nM). Pan-rasin-2 has significant inhibitory activity on cell proliferation of RAS mutant cell lines. Pan-rasin-2 can form ternary complexes with cyclophilin A (CYPA) and RAS (ON) proteins and the formation of ternary complexes can block the binding of RAF downstream of RAS, which has anti-tumor (such as colorectal cancer, pancreatic cancer) effects [1].
    Pan-RAS-IN-2
  • HY-10805A
    Almorexant hydrochloride
    5+ Cited Publications

    ACT 078573 hydrochloride

    		 Orexin Receptor (OX Receptor) Calcium Channel Caspase Apoptosis Neurological Disease Endocrinology Cancer
    Almorexant (ACT 078573) hydrochloride is an orally active, potent and competitive dual orexin receptor antagonist, with Kd values of 1.3 nM (OX1) and 0.17 nM (OX2), respectively. Almorexant hydrochloride reversibly blocks signaling of orexin-A and orexin-B peptides. Almorexant hydrochloride totally blocked the intracellular Ca 2+ signal pathway. Almorexant hydrochloride stimulates caspase-3 activity in AsPC-1 cells and induces apoptosis [1] .
    Almorexant hydrochloride
  • HY-148098
    Pan KRas-IN-1
    1 Publications Verification

    		 Ras Cancer
    Pan KRas-IN-1 is a pan KRas inhibitor, can be used for agent resistance in cancer developed with KRas G12C inhibitors [1].
    Pan KRas-IN-1
  • HY-114657A
    Benproperine phosphate
    2 Publications Verification

    		 Arp2/3 Complex Inflammation/Immunology Cancer
    Benproperine phosphate is an orally active, potent actin-related protein 2/3 complex subunit 2 (ARPC2) inhibitor. Benproperine phosphate attenuates the actin polymerization rate of action polymerization nucleation by impairing Arp2/3 function. Benproperine phosphate has the potential for a cough suppressant and suppresses cancer cell migration and tumor metastasis [1].
    Benproperine phosphate
  • HY-161176
    PROTAC KRAS G12D degrader 1

    		PROTACs Ras ERK Cancer
    PROTAC KRAS G12D degrader 1 is a selective PROTAC KRAS G12D degrader. PROTAC KRAS G12D degrader 1 inhibits proliferation of KRAS G12D-mutant cells and suppresses ERK phosphorylation. PROTAC KRAS G12D degrader 1 inhibits tumor growth in mice bearing AsPC-1 xenografts. PROTAC KRAS G12D degrader 1 can be used for the study of KRAS G12D-driven cancers.(Pink: KRAS ligand (HY-175892), Blue: VHL Ligand (HY-112078), Black: Linker, E3 ligase ligand-linker conjugate (HY-175893)) [1].
    PROTAC KRAS G12D degrader 1
  • HY-148685
    KM04416
    1 Publications Verification

    		 Aldehyde Dehydrogenase (ALDH) Cancer
    KM04416, an isothiazolone derivative, is a potent glycerol-3-phosphate dehydrogenase (GPD2) inhibitor. KM04416 significantly inhibits PNT1A cell proliferation [1] .
    KM04416
  • HY-176134
    RP03707

    		PROTACs Ras Cancer
    RP03707 is a PROTAC degrader of KRAS G12D. RP03707 forms a ternary complex with KRAS G12D and the CRBN E3 ligase, promoting the ubiquitination and proteasomal degradation of KRAS G12D. RP03707 inhibits the growth of KRAS G12D-positive tumor cells [1].
    RP03707
  • HY-174304
    Bis(vinylsulfonyl)piperazine-triazole-PEG3-O-diisopropylsilyl-triptolide

    		Drug-Linker Conjugates for ADC Cancer
    Bis (vinylsulfonyl) piperazine-triazole-PEG3-O-diisopropylsilyl-triptolide is a drug-linker conjugates for ADC. Bis (vinylsulfonyl) piperazine-triazole-PEG3-O-diisopropylsilyl-triptolide consists of Triptolide (HY-32735) and a stable cleavable linker (Bis (vinylsulfonyl) piperazine-triazole-PEG3-O-diisopropylsilyl-Cl) (HY-174810). Bis (vinylsulfonyl) piperazine-triazole-PEG3-O-diisopropylsilyl-triptolide can be used for the synthesis of antibody-drug conjugates (ADCs) [1].
    Bis(vinylsulfonyl)piperazine-triazole-PEG3-O-diisopropylsilyl-triptolide
  • HY-164350
    KRAS inhibitor-27

    		Ras ERK p38 MAPK Cancer
    KRAS inhibitor-27 (Compound 15h) is the inhibitor for KRAS. KRAS inhibitor-27 inhibits KRAS G12D/G12V mutated cells AsPC-1, SW620 and KRAS wildtype cell HT-29 with IC50 of 378, 0.6 and 3230 nM, respectively. KRAS inhibitor-27 inhibits ERK phosphorylation (IC50 in cell AsPC-1 and SW620 is 0.6 nM and 1 nM), reduces the expression of DUSP4, thereby inhibiting MAPK signaling pathway [1].
    KRAS inhibitor-27
  • HY-162809
    XMU-MP-9

    		Ras Cancer
    XMU-MP-9 is a bifunctional compound that binds to the C2 domain of Nedd4-1 and the allosteric site of K-Ras. XMU-MP-9 enhances the interaction between Nedd4-1 and K-Ras, induces conformational changes in the Nedd4-1/K-Ras complex, promotes the ubiquitination and degradation of multiple K-Ras mutants, and inhibits the proliferation of cells carrying K-Ras mutants. XMU-MP-9 can be used for the study of colon, lung and pancreatic cancer [1].
    XMU-MP-9
  • HY-P10387
    RSM3
    1 Publications Verification

    		 METTL3 Apoptosis MDM-2/p53 NF-κB Caspase Cancer
    RSM3 is a METTL3-METTL14 complex inhibitor with a Kd of 3.10 μM for the METTL3-METTL14 complex. RSM3 reduces the m 6A modification level of SLC31A1 and the global RNA methylation level. RSM3 upregulates programmed cell death-related genes, enhances cell apoptosis, inhibits pro-cancer signals and suppresses tumor growth. RSM3 is applicable to the research of preeclampsia and cancer [1] .
    RSM3
  • HY-175870
    Eras-4001

    		Ras Cancer
    Eras-4001 (Compound 14-1) is a pan-KRAS inhibitor. Eras-4001 has potent antitumor activities and significantly inhibits the proliferation of wild-type and mutant (such as KRAS G12D, KRAS G12V and KRAS G12C) cancer cells. Eras-4001 effectively inhibits tumor growth in GP2D and Panc0403 xenograft mouse models [1].
    Eras-4001
  • HY-178836
    Z56-L23

    		Drug-Linker Conjugates for ADC Ras Cancer
    Z56-L23 is a conjugate of RAS-targeting ADC cytotoxic payload-linker with anti-tumor activity. Z56-L23 can be conjugated with HER3 antibody, EGFR antibody or EGFRxHER3 bispecific antibody to form intact antibody-drug conjugates (ADCs). ADC molecules related to Z56-L23 effectively inhibit the proliferation of tumor cells and also significantly suppress tumor growth in xenograft mouse models. Z56-L23 can be used in the research of pancreatic cancer [1].
    Z56-L23
  • HY-157029S
    KRASG12D-IN-1

    		Ras Cancer
    KRASG12D-IN-1 (compound 22) is a KRAS G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition [1].
    KRASG12D-IN-1
  • HY-14653
    Amsilarotene

    TAC-101; Am 555S

    		 RAR/RXR Apoptosis Cancer
    Amsilarotene (TAC-101; Am 555S), an orally active synthetic retinoid, has selective affinity for retinoic acid receptor α (RAR-α) binding with Ki of 2.4, 400 nM for RAR-α and RAR-β. Amsilarotene induces the apoptotic of human gastric cancer, hepatocellular carcinoma and ovarian carcinoma cells. Amsilarotene can be used for the research of cancer [1] .
    Amsilarotene
  • HY-158008
    (R)-G12Di-7

    		Ras Cancer
    (R)-G12Di-7 is a covalent ligand for KRAS-G12D, which selectively labels K-Ras-G12D·GDP and K-Ras-G12D·GppNHp. (R)-G12Di-7 exhibits inhibitory activity against G12D mutated cancer cells [1].
    (R)-G12Di-7
  • HY-162749A
    G9D-4 TFA

    		PROTACs Histone Methyltransferase Apoptosis Cancer
    G9D-4 TFA is a G9a PROTAC degrader. G9D-4 TFA induces G9a degradation, reduces H3K9me2 levels, and prevents GLP interference via the CRBN ternary complex, proteasome and ubiquitin-like modification-dependent pathways. G9D-4 TFA exerts antiproliferative activity and induces Apoptosis in pancreatic cancer cells. G9D-4 TFA can be used for research on pancreatic cancer [1].
    G9D-4 TFA
  • HY-157031S
    KRASG12D-IN-2

    		Ras Cancer
    KRASG12D-IN-2 (compound 28) is a KRAS G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition [1].
    KRASG12D-IN-2
  • HY-162749
    G9D-4

    		PROTACs Histone Methyltransferase Apoptosis Cancer
    G9D-4 is a G9a PROTAC degrader. G9D-4 induces G9a degradation, reduces H3K9me2 levels, and prevents GLP interference via the CRBN ternary complex, proteasome and ubiquitin-like modification-dependent pathways. G9D-4 exerts antiproliferative activity and induces Apoptosis in pancreatic cancer cells. G9D-4 can be used for research on pancreatic cancer [1].
    G9D-4
  • HY-149393
    RIPK3-IN-3

    		Mixed Lineage Kinase RIP kinase Cancer
    RIPK3-IN-3 (compound 20) is a selective inhibitor of RIP kinase RIPK3 (IC50=10 nM). RIPK3 mediates the phosphorylation of Mixed Lineage Kinase (MLKL) and causes necroptosis, while RIPK3-IN-3 inhibits p-MLKL oligomerization and thereby inhibits necroptosis. RIPK3-IN-3 also downregulates CXCL5 secretion and inhibits AsPC-1 cell migration and invasion [1].
    RIPK3-IN-3
  • HY-175025
    CH091138

    		PROTACs Ras Apoptosis Cancer
    CH091138 is a potent and selective KRASG12D PROTAC degrader with DC50s of 148.3 nM in HeLa cells and 469.8 nM in AsPC-1 cells. CH091138 selectively degrades exogenous and endogenous KRASG12D but not KRAS WT or other KRAS mutants (G12C/G12S/G12V), depending on the VHL-mediated ubiquitin-proteasome system. CH091138 exhibits potent anti-tumor activity and induces cancer cell apoptosis. CH091138 can be used for the studies of pancreatic cancer and colon cancer. (Pink: KRASG12D ligand (HY-175144); Blue: VHL E3 ligase ligand (HY-138678); Black: Linker; VHL E3 ligase ligand + Linker (HY-136006B)) [1].
    CH091138
  • HY-157762
    GPX4-IN-9

    		Glutathione Peroxidase Ferroptosis Cancer
    GPX4-IN-9 (Compound A16) is a glutathione peroxidase 4 (GPX4) inhibitor that specifically targets GPX4 under both in vitro and in vivo conditions, inducing ferroptosis. GPX4-IN-9 exhibits cytotoxicity against pancreatic cancer cells and can be used in cancer research [1].
    GPX4-IN-9
  • HY-162445
    KRASG12D-IN-3

    		Ras PERK Cancer
    KRASG12D-IN-3 is an orally active KRAS G12D inhibitor. KRASG12D-IN-3 inhibits the growth of gastric cancer and pancreatic cancer cells. KRASG12D-IN-3 inhibits the activity of p-ERK in gastric cancer cells. KRASG12D-IN-3 can be used for the research of gastric cancer and pancreatic cancer [1].
    KRASG12D-IN-3
  • HY-178497
    ZJK-807

    		PROTACs Ras p38 MAPK TNF Receptor Inflammation/Immunology Cancer
    ZJK-807 is a highly effective and selective PROTAC degrader targeting KRASG12D (DC50 = 79.5 nM in AsPC-1 cells). ZJK-807 shows minimal impact on wild-type KRAS or other mutants (G12C/S/V, G13D), inducing mutant-specific cytotoxicity. ZJK-807 suppresses RAS/MAPK signaling and uniquely modulates TNF signaling and eukaryotic ribosome biogenesis. ZJK-807 can be used for the study of KRAS-driven pancreatic cancer. Yellow: KRASG12D ligand (HY-W087383); Green: E3 ligase CRBN ligand (HY-178507); Black: Linker (HY-178506) [1].
    ZJK-807
  • HY-162440
    pan-KRAS-IN-7

    		Ras Cancer
    pan-KRAS-IN-7 (Compound 25) is an inhibitor for in human tumor mutated genes KRAS, which inhibits proliferation of KRAS mutated cells AsPC-1 (G12D mutant) and SW480 (G12V mutant) with IC50 of 0.35 and 0.51 nM, respectively [1].
    pan-KRAS-IN-7
  • HY-162443
    pan-KRAS-IN-10

    		Ras Cancer
    pan-KRAS-IN-10 (Compound 58) is an inhibitor for in human tumor mutated genes KRAS, which inhibits proliferation of KRAS mutated cells AsPC-1 (G12D mutant) and SW480 (G12V mutant) with IC50 of 0.7 and 0.24 nM, respectively [1].
    pan-KRAS-IN-10
  • HY-137046
    Nek2-IN-4

    		NEKs Cancer
    Nek2-IN-4 is a potent NEK2 inhibitor with an IC50 value of 15 nM. Nek2-IN-4 inhibits cell proliferation. Nek2-IN-4 has the potential for the research of pancreatic cancer [1].
    Nek2-IN-4
  • HY-149511
    MET/PDGFRA-IN-2

    		c-Met/HGFR Apoptosis PDGFR Cancer
    MET/PDGFRA-IN-2 (compound 8h) is a MET and PDGFRA protein inhibitor. MET/PDGFRA-IN-2 induces cell apoptosis. MET/PDGFRA-IN-2 inhibits proliferation of MET-positive cells (IC50s: 9.7, 6.1, 12.0, 11.5, 8.6, 34.4 μM for AsPc-1, EBC-1, MKN-45, Mia-Paca-2, HT-29, K562 cells respectively) [1].
    MET/PDGFRA-IN-2
  • HY-149510
    MET/PDGFRA-IN-1

    		c-Met/HGFR Apoptosis PDGFR Cancer
    MET/PDGFRA-IN-1 (compound 8c) is a MET and PDGFRA protein inhibitor (IC50: 36 μM for MET). MET/PDGFRA-IN-1 inhibits MET phosphorylation and induces cell apoptosis. MET/PDGFRA-IN-1 inhibits proliferation of MET-positive cells (IC50s: 15.3, 19.0, 22.0, 25.6, 21.0, 31.5 μM for AsPc-1, EBC-1, MKN-45, Mia-Paca-2, HT-29, K562 cells respectively) [1].
    MET/PDGFRA-IN-1
  • HY-174243
    KRASG12D-IN-5

    		Ras Cancer
    KRASG12D-IN-5 (Compound 241) is an orally active KRAS(G12D) inhibitor with an IC50 of 11 nM. KRASG12D-IN-5 has potent anticancer activity with no significant cytotoxicity against BxPC-3 (WT), KRAS mutation AsPC-1 (G12D) and MIAPaCa-2 cells (G12C) with CC50s of 10.37, 0.76 and 0.3 μM, respectively. KRASG12D-IN-5 can be used for cancer research, such as lung, pancreatic and colorectal cancer [1].
    KRASG12D-IN-5
  • HY-163488
    KRASG12D-IN-4

    		Ras Cancer
    KRASG12D-IN-4 (example 38) is a KRas G12D inhibitor with an IC50 of 3.3 nM. KRASG12D-IN-4 inhibits proliferation of pancreatic cancer ASPC-1 cells with an IC50 of 12 nM [1].
    KRASG12D-IN-4
  • HY-175529
    KRASG12D-IN-7

    		Ras ERK Apoptosis Cancer
    KRASG12D-IN-7 is a selective KRAS G12D inhibitor. KRASG12D-IN-7 displays strong binding activity for KRAS G12D in both its GDP- and GTP- bound states, with Kd value of 1.12 nM and 1.86 nM, respectively. KRASG12D-IN-7 inhibits the proliferation of KRAS G12D harboring AsPC-1 cells with an IC50 value of 10 nM and suppresses MAPK signaling. KRASG12D-IN-7 induces G0/G1 phase arrest and apoptosis in AsPC-1 cells, and strongly inhibits their colony formation. KRASG12D-IN-7 can be used for the study of cancers harboring KRAS G12D mutation, particularly pancreatic ductal adenocarcinoma (PDAC) [1].
    KRASG12D-IN-7
  • HY-181067
    IK-595

    		MEK ERK Cancer
    IK-595 is a MEK1/MEK2 inhibitor with high affinity (7.39 nM).IK-595 blocks EGF-induced ERK1/2 phosphorylation in AsPC-1 cells with IC50 value of 0.1 nM. IK-595 has oral activity and blood-brain barrier penetration. IK-595 can be used for the research of Ras/MAPK pathway-altered cancers [1].
    IK-595
  • HY-173124
    CDK2/FLT4/PDGFRA-IN-1

    		CDK VEGFR PDGFR Apoptosis Cancer
    CDK2/FLT4/PDGFRA-IN-1 (Compound 4a) is a potent inhibitor of CDK2/cyclin A, FLT4 (VEGFR3) and PDGFRA, with IC50s of 1.672, 0.554, and 0.629 μM, respectively. CDK2/FLT4/PDGFRA-IN-1 exhibits potent antiproliferative effects against cancer cells (lung EBC-1, pancreatic ductal adenocarcinoma AsPC-1, colorectal HT-29 cells). CDK2/FLT4/PDGFRA-IN-1 can also induce apoptosis in cancer cells [1].
    CDK2/FLT4/PDGFRA-IN-1
  • HY-158726
    Complex 3

    		Fluorescent Dye Apoptosis Cancer
    Complex 3 is a fluorescent dithiocarbazate-copper complex with anticancer activity, which localizes to mitochondria. Complex 3 displays excitation/emission maxima of 455-495/535 nm, respectively. Complex 3 inhibits the growth of BxPC-3, AsPC-1, PANC-1, and WI38 pancreatic cancer cells with IC50 values of 0.74, 0.41, 0.62, and 2.06 µM, respectively. Complex 3 induces lipid peroxidation and mitochondrial rupture and shrinkage in AsPC-1 cells. Complex 3 also induces mitochondrial apoptosis and cytokine-cytokine receptor interaction dysfunction in AsPC-1 cells. Complex 3 reduces tumor volume in an AsPC-1 mouse xenograft model [1].
    Complex 3
  • HY-162441
    pan-KRAS-IN-8

    		Ras Cancer
    pan-KRAS-IN-8 (Compound 38) is an inhibitor for in human tumor mutated genes KRAS, which inhibits proliferation of KRAS mutated cells AsPC-1 (G12D mutant) and SW480 (G12V mutant) with IC50 of 0.07 and 0.18 nM, respectively [1].
    pan-KRAS-IN-8
  • HY-162442
    pan-KRAS-IN-9

    		Ras Cancer
    pan-KRAS-IN-9 (Compound 52) is an inhibitor for in human tumor mutated genes KRAS, which inhibits proliferation of KRAS mutated cells AsPC-1 (G12D mutant) and SW480 (G12V mutant) with IC50 of 0.24 and 0.30 nM, respectively [1].
    pan-KRAS-IN-9
  • HY-162536
    Pan-RAS-IN-5

    		Molecular Glues Cyclophilin Ras Cancer
    Pan-RAS-IN-5 (compound 7A) is a molecular glues that can form a ternary complex with the proteins cyclophilin A (CYPA) and RAS (ON). The formation of the ternary complex can block the binding of RAS downstream of RAF and has anti-tumor effects [1].
    Pan-RAS-IN-5
  • HY-162444
    KRAS G12D inhibitor 22

    		Ras Cancer
    KRAS G12D inhibitor 22 (compound 6) is a inhibitor of KRAS mutation. KRAS G12D inhibitor 22 has high activity (IC50＜100 nM), good selectivity and low toxicity.KRAS G12D inhibitor 22 can be used in breast cancer research [1].
    KRAS G12D inhibitor 22
  • HY-162439
    pan-KRAS-IN-6

    		Ras Cancer
    pan-KRAS-IN-6 (compound 12) is a potent pan KRAS inhibitor with IC50 values of 9.79 nM (Kras G12D) and 6.03 nM (Kras G12V) [1].
    pan-KRAS-IN-6
  • HY-161630
    TLR8 agonist 8

    		Toll-like Receptor (TLR) Cancer
    TLR8 agonist 8 (Compound II-72) is an agonist for Toll-like receptor 8 (TLR8) with EC50 of 0.25-1 μM. TLR8 agonist 8 is stable in human and murine plasma, induces secretion of cytokines TNFα, with EC50 <1 μM. TLR8 agonist 8 exhibits antitumor activity in MC38-HER2 xenograft mouse model with a tumor growth inhibition (TGI) rate of 89% [1].
    TLR8 agonist 8
  • HY-10805R
    Almorexant (Standard)

    ACT 078573 (Standard)

    		 Orexin Receptor (OX Receptor) Calcium Channel Caspase Apoptosis Reference Standards Neurological Disease Endocrinology Cancer
    Almorexant (Standard) is the analytical standard of Almorexant. This product is intended for research and analytical applications. Almorexant (ACT 078573) is an orally active, potent and competitive dual orexin receptor antagonist, with Kd values of 1.3 nM (OX1) and 0.17 nM (OX2), respectively. Almorexant reversibly blocks signaling of orexin-A and orexin-B peptides. Almorexant totally blocked the intracellular Ca2+ signal pathway. Almorexant stimulates caspase-3 activity in AsPC-1 cells and induces apoptosis [1] .
    Almorexant (Standard)
  • HY-173044
    5-HT1AR/5-HT6R ligand-1

    		5-HT Receptor Dopamine Receptor Neurological Disease
    5-HT1AR/5-HT6R ligand-1 (Compound PP13) is the ligand for 5-HT receptor that exhibits good affinity to 5-HT1AR, 5-HT6R and 5-HT7R (Ki of 19, 69 and 198 nM, respectively), thereby inhibiting the cAMP production in HEK293 cell with EC50 of 1535, 488 and 53 nM, respectively. 5-HT1AR/5-HT6R ligand-1 exhibits anti-proliferative activity against a variety of cancer cells (IC50 for 1321N1, U87MG, MCF7, and AsPC-1 is 9.6, 13.6, 19.3 and 14.6 μM, respectively). 5-HT1AR/5-HT6R ligand-1 also exhibits antagonist activity for dopamine receptor D2R with Ki of 1903 nM [1].
    5-HT1AR/5-HT6R ligand-1
  • HY-N11572
    Anticancer agent 96

    		Others Cancer
    Anticancer agent 96 (Compound 4) is an anticancer agent that shows cytotoxic activities against human cancer cells [1].
    Anticancer agent 96
  • HY-170313
    GLUT-1-IN-4

    		GLUT Apoptosis Reactive Oxygen Species (ROS) Cancer
    GLUT-1-IN-4 (Compound 13) is the p53 protein-dependent inhibitor for GLUT-1 glucose transporter. GLUT-1-IN-4 inhibits the proliferation of multiple cancer cells with IC50 in submicromolar levels. GLUT-1-IN-4 arrests the cell cycle, stimulates oxidative stress, and induces apoptosis [1].
    GLUT-1-IN-4
  • HY-173043
    5-HT6R antagonist 6

    		5-HT Receptor Cancer
    5-HT6R antagonist 6 exhibits high affinity and selectivity for 5-HT6R , with a Ki value of 42 nM. 5-HT6R antagonist 6 shows weak antiproliferative activity against tumor cells and low toxicity to normal cells. 5-HT6R antagonist 6 can be used in the study of cancer [1].
    5-HT6R antagonist 6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: